Adial Pharmaceuticals, Inc (NASDAQ:ADIL) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of prefunded warrants Update: about US$32M Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital Insiders: Insiders and management participated Use of proceeds: Fund operations into 2028, including IND-enabling studies and initiation of the Phase 1 trial of AT177 in ulcerative colitis | Oct 28, 2026 |
| Private placement of pre-funded warrants and common warrants Tranche closed: US$32M raised · US$2.7489 a share · common warrants to purchase up to 11,780,948 shares of common stock, sold with… · Lucid Capital Markets +1 Dealers: Lucid Capital Markets (lead), TD Cowen Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital (one of the lead investors) Insiders: insiders and management participated Use of proceeds: Advance its lead colon-targeted AhR program through key clinical milestones | Jun 16, 2026 |
| Warrant exercise of series C-1 and Series E warrants exercised for common stock Announced: about US$2.86M · US$0.31 a share · Warrants at US$0.31 for 24 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners Buyers: existing healthcare-focused institutional investor (exercising the Existing Warrants for approximately $2.86 million) Use of proceeds: Working capital and other general corporate purposes | Nov 26, 2025 |
| Public offering of shares of common stock with Series D and Series E warrants Announced: about US$3.6M · US$0.3251 a share · Warrants at US$0.35 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Working capital and general corporate purposes | Jun 17, 2025 |
| Warrant exercise of series B and Series C Warrants exercised for common stock Announced: about US$2.75M · US$0.74 a share · Warrants at US$0.74 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners Use of proceeds: Working capital and other general corporate purposes | May 2, 2025 |